• Pelage Pharma

  Participated · Series B · Oct 2025

  Pelage Pharmaceuticals is a regenerative-medicine biotechnology company focused on first-in-class treatments for hair loss in both men and women. Its science centers on stem cell biology and metabolism, aiming to restore the body’s natural ability to grow hair by reactivating dormant hair-follicle stem cells. The company’s lead asset, PP405, is a non-invasive topical small molecule currently being evaluated in Phase 2a clinical trials. Proceeds from the most recent financing will be directed toward advancing PP405 through mid-stage development and expanding Pelage’s broader pipeline of hair-regeneration therapies. Led by CEO Daniel Gil, Ph.D., Pelage’s leadership team includes co-founder and President William Lowry, Ph.D. The firm has also strengthened its governance, appointing Cathy Friedman (GV) as Board Chair and adding Richard Heyman, Ph.D. (ARCH) to its board. The fresh capital positions Pelage to accelerate clinical progress and prepare for later-stage studies.

• Iantrek

  Participated · Series C · Aug 2025

  Iantrek develops minimally invasive surgical technologies and biologic tissue solutions aimed at restoring the eye’s natural fluid outflow pathways to treat chronic eye diseases such as glaucoma. The company launched its lead commercial product, AlloFlo Uveo, in October 2025 and has introduced AlloSpan Canal in the U.S. Iantrek positions its portfolio to offer complementary surgical solutions targeting both natural outflow pathways for a more comprehensive, physiologic approach to glaucoma intervention. Following a Series C in 2025 led by USVP, Sectoral, aMoon, and Visionary Ventures, Iantrek secured a $30 million debt facility from Trinity Capital to accelerate commercial expansion and advance its pipeline and regulatory work. The company plans to scale manufacturing and distribution capabilities and strengthen market access to broaden physician and patient adoption.

• Orasis Pharmaceuticals

  Participated · Series D · Oct 2024

  Orasis Pharmaceuticals developed Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a corrective eye drop indicated for the treatment of presbyopia in adults. Qlosi uses the lowest effective concentration of pilocarpine approved and a multi-faceted vehicle, does not contain an antimicrobial preservative, and improves near visual acuity via pupil modulation (a "pinhole effect"). The company emphasizes a balance of efficacy, safety, and comfort for patients seeking an alternative to reading glasses. Orasis plans to use the new financing to support the commercial launch of Qlosi. The company is led by industry executives and eye care professionals and is funded by a diverse group of life-science and healthcare investors. Orasis has offices in the United States and Israel. Orasis Pharmaceuticals, based in Herzliya, Israel, is developing a proprietary ophthalmic formulation intended to treat presbyopia symptoms. Its lead candidate is an eye drop designed to achieve an optimal balance between efficacy, safety and comfort. The company plans to use the Series C proceeds to advance that lead eye drop through completion of Phase 3 clinical trials and to fund pre-commercialization activities ahead of a potential product launch. Orasis is led by CEO Elad Kedar. The company positions its novel formulation to potentially make it an emerging leader in the presbyopia space. It closed a $30M Series C financing to support these programs. Orasis Pharmaceuticals, led by CEO Elad Kedar and based in Herzliya, Israel, is a clinical-stage company developing an innovative eye drop to treat presbyopia as an alternative to reading glasses. Its lead product candidate, CSF-1, is being advanced through clinical development. The company intends to use the new funding to complete its Phase 2b trial of CSF-1, prepare for a Phase 3 trial, and continue pre-commercial activities ahead of a potential launch. Orasis closed a financing that supports these near-term clinical and commercial milestones. The company added board members from its new investors as part of the financing.

• ONL Therapeutics

  Participated · Series D · Sep 2024

  ONL Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to protect and improve vision in patients with retinal disease, specifically geographic atrophy (GA) associated with dry AMD. The firm targets a mechanism of action that prevents Fas-mediated death of retinal cells and inflammatory signaling pathways, which it cites as root causes of vision loss. Its lead candidate, ONL1204 Ophthalmic Solution, showed reductions in the rate of growth of GA lesions in a Phase 1b trial after six months with either a single injection or two injections 90 days apart versus sham. A consistent treatment effect was observed when comparing treated eyes to fellow eyes. The company is led by CEO David Esposito and co-founder and chief scientific officer David Zacks, M.D., Ph.D. ONL plans to use the new financing to expand development efforts and further advance its differentiated clinical program in GA. ONL Therapeutics is a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, developing first-in-class therapeutics to protect retinal cells from Fas-mediated cell death. Its lead asset, ONL1204 Ophthalmic Solution, is a novel small-molecule Fas inhibitor intended to protect photoreceptors and other retinal cells across a range of retinal diseases. ONL1204 has an active IND and has been granted orphan drug designation by the FDA for macula-off rhegmatogenous retinal detachment (RRD). The company is preparing to initiate a U.S.-based Phase 2 study in macula-off RRD next quarter and is conducting two ongoing Phase 1b studies in geographic atrophy (GA) associated with AMD and in progressing open-angle glaucoma (OAG) at sites in Australia and New Zealand. Preclinical work is ongoing to enable trials in other indications, including inherited retinal degeneration. The recently announced financing will support advancement of ONL1204 into Phase 2 and regulatory preparations for additional Phase 2 programs in GA and OAG. ONL Therapeutics, based in Ann Arbor, Michigan, is developing novel therapies to protect vision in patients with retinal disease. Its lead compound, ONL1204, is a novel small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from Fas-mediated cell death. The company is building a platform of products intended for a range of blinding diseases, including retinal detachment, glaucoma, age-related macular degeneration (AMD), and inherited retinal degeneration (IRD). ONL1204 has been granted orphan drug designation by the U.S. FDA for retinal detachment, and the company has focused initial clinical plans on the acute indication of retinal detachment while pursuing preclinical work for chronic indications. Planned clinical activity includes completing a Phase 1 study in retinal detachment and initiating Phase 1b studies in open-angle glaucoma and dry AMD, plus a repeat-dose toxicology study to support accelerated chronic dosing. The company is led by CEO David Esposito and co-founder/CSO David Zacks, M.D., Ph.D. ONL Therapeutics is developing a platform of Fas inhibitors intended to protect key retinal cells and preserve vision across a range of retinal diseases. Its lead compound, ONL1204, is a novel, first-in-class small-molecule Fas inhibitor designed to protect photoreceptors and other retinal cells from cell death. ONL1204 has been granted orphan drug designation by the U.S. FDA for the treatment of retinal detachment. The company is preparing ONL1204 for a Phase I study in retinal detachment to be conducted in Australia later in 2019. ONL is pursuing a Series B to continue funding clinical development and to expand its Fas inhibitor pipeline into indications including glaucoma, age-related macular degeneration, and inherited retinal degeneration. Financially, ONL recently raised $3 million in a convertible note from a mix of current investors, management, and new investors to advance its clinical program. ONL Therapeutics is developing ONL1204, a novel first‑in‑class small‑molecule Fas inhibitor designed to prevent retinal cell death via direct and inflammatory signaling. The company is initially advancing ONL1204 toward clinical trials for retinal detachment, where the compound has received U.S. FDA orphan drug designation. Preclinical data and literature cited by the company support potential application of ONL1204 in glaucoma, wet and dry age‑related macular degeneration (AMD), non‑infectious uveitis and other retinal neuropathies. ONL closed a $4.25 million Series A and combined those proceeds with a recently announced $1.0 million grant from the National Eye Institute to finalize preclinical development. The financing also included conversion of a previously announced $1.0 million bridge loan. Funds will be used to complete preclinical work, prepare for first‑in‑human trials, and broaden research into other ocular indications with significant unmet need.

• Re-Vana Therapeutics

  Led · Series A · Nov 2022

  Re-Vana Therapeutics develops proprietary photo-crosslinked, biodegradable sustained-release ophthalmic drug-delivery technologies, including EyeLief®, EyeLief-SD™ and OcuLief®. The company aims to reduce the frequency of intravitreal injections for a range of retinal diseases, including neovascular age-related macular degeneration (wet AMD). Re-Vana intends to use recent financing to advance development of its drug-delivery platforms and to expand operations and development teams. Founded in 2016 as a spin-out from Queen's University Belfast, the company is headquartered in Belfast with a U.S. office in Tampa, Florida. Its technology may enable a broader set of sustained-release products across multiple therapeutic areas. The company strengthened its board in conjunction with the financing, appointing Robert Avery, M.D., of Visionary Ventures and InFocus Capital Partners as a board member and naming Michael O’Rourke as board chair. Re-Vana closed a Series A round totaling $11.9M to support these plans. Re-Vana Therapeutics is developing proprietary photocrosslinked EyeLief™ and OcuLief™ biodegradable technologies to deliver biologic and small-molecule therapeutics for retinal and other ocular diseases. The platform has demonstrated at least four months sustained release of an anti-VEGF drug with greater than 50% drug loading and targets 4–6 months delivery for large-molecule biologics and 6–9 months for small molecules. Proceeds from recent financing will advance proof-of-concept and preclinical development and enable expansion of the company’s research and development team. Re-Vana also holds rights to a novel nanoparticle polymer–based drug delivery technology for ophthalmic applications. The company was founded in 2016 as a spin-out from Queen’s University Belfast and maintains its main office in Belfast with a U.S. office in Tampa, Florida. Re-Vana has previously received Innovate U.K. funding (more than $400K) and entered a 2020 strategic feasibility collaboration with a global pharmaceutical company.

No current team members are available.